ViroPharma Sees 2012 Sales of $600-660M vs $593M Est

ViroPharma Incorporated

today announced that Vincent Milano, president and chief executive officer of ViroPharma, will provide an overview of the company's business during the 30th Annual J.P. Morgan Healthcare Conference. For the year 2012, ViroPharma expects the following: Worldwide net product sales are expected to be $600 to $660 million Net U.S. Cinryze sales are expected to be $310 to $330 million. Net Vancocin sales are expected to be $260 to $310 million; and Research and development (R&D) and selling, general and administrative (SG&A) expenses are expected to be $230 to $260 million.